evidoria

← Back to browse

Good practice Imported

Inven2 - Oslo University & Hospital Technology Transfer Office

Norway · Oslo · See the Norway profile · See the Oslo profile

Evidence: Descriptive / self-reported Top 84% 52/100 · Ask Evidence Copilot about this practice

Inven2, the technology-transfer office jointly owned by the University of Oslo and Oslo University Hospital, managed a portfolio of about 50 companies in 2024 that raised NOK 670 million for development and returned NOK 24 million in licensing income to research.

670 NOK million
Development capital raised by portfolio companies (2024) (2024)
333 NOK million
Development capital raised by portfolio companies (2023) (2023)
24 NOK million
Returned to research/innovation via licence income and share sales (2024) (2024)
36 NOK million
Returned to research/innovation via licence income and share sales (2023) (2023)
125 projects
Ongoing commercialisation projects (end of 2023)
roughly 11 billion (2023) to roughly 5 billion (2024) NOK billion
Portfolio combined value (caveat: year-on-year swing unexplained in source) (2023-2024)
Inven2 - Oslo University & Hospital Technology Transfer Office

Details

Maturity
Established
Promoter
Inven2
Period
2010-2024
Region (NUTS)
NO01
Keywords
technology transfer, university and hospital tech transfer, licensing, venture financing, life sciences

Context

Inven2 was formed in 2010 through the merger of Medinnova (Rikshospitalet's technology transfer office), Birkeland Innovasjon and the University of Oslo's own TTO. It is jointly owned by the University of Oslo and Oslo University Hospital, and also administers commercialisation of inventions across the wider South-Eastern Norway Regional Health Authority; an independent review by patent-law firm Dehns describes it as the largest technology transfer office in the Nordic region.

Activities

Inven2 manages a portfolio of roughly 50 companies, supporting commercialisation of research inventions and administering licensing and venture financing, with 125 ongoing commercialisation projects at the end of 2023.

Results

In 2024, Inven2's portfolio (2 newly established companies that year) raised NOK 670 million for development, up from NOK 333 million in 2023, while NOK 24 million was returned to research and innovation through licence income and share sales in 2024 (NOK 36 million in 2023).

Conclusions

The portfolio's reported combined value swung from roughly NOK 11 billion in 2023 to roughly NOK 5 billion in 2024 in Inven2's own summaries, a large year-on-year shift that is not explained in available sources and should be treated cautiously. Only 2 new companies were formed in 2024 despite the higher capital raised, suggesting the model is currently oriented toward scaling existing portfolio companies rather than high-volume new spin-off creation.

Implementation
Indicative cost
Very high (> €5M) — Portfolio of roughly 50 companies; NOK 670 million raised for development in 2024 (up from NOK 333 million in 2023); reported combined portfolio value of roughly NOK 5–11 billion (year-on-year figures inconsistent in the source).
Time to results
Long (> 3 years) — Operating continuously since formation in 2010 through at least 2024.
Staffing & skills
Inven2 technology-transfer office staff (joint TTO of the University of Oslo and Oslo University Hospital)

Conditions for success

  • Merger of three prior technology-transfer offices (Medinnova, Birkeland Innovasjon, University of Oslo's TTO) into a single larger office
  • Administers commercialisation across the wider South-Eastern Norway Regional Health Authority, giving it a larger deal pipeline

Common failure modes

  • Portfolio's reported combined value swung from roughly NOK 11 billion (2023) to roughly NOK 5 billion (2024) in Inven2's own summaries, a large year-on-year shift not explained in available sources
  • Only 2 new companies were formed in 2024 despite higher capital raised, suggesting a shift toward scaling existing companies rather than new spin-off creation

Commonly funded by

National / regional programmes

Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.

Do you run this practice? Claim it — verified implementers get a public contact pathway and can propose corrections.

Data sources

Where this practice's information was retrieved from, and when.

Attachments

Similar practices you may find useful